OncoPharm Podcast Por John Bossaer arte de portada

OncoPharm

OncoPharm

De: John Bossaer
Escúchala gratis

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.All rights reserved Ciencia
Episodios
  • HOPA 2026 Recap

    HOPA 2026 Recap
    Apr 2 2026
    Recapping what I learned at HOPA 2026: -Beyond steroids for irAs -IT chemo beyond methotrexate and cytarabine -Pre-emptive CMV management in patients receiving certain bispecifics -semaglutide-alectinib drug interaction -Safety (n = ~40) of MMR vaccine in patients post-Auto transplant on maintenance daratumumab Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
    Más Menos
    14 m
  • Nivo-AVD Approval

    Nivo-AVD Approval
    Mar 24 2026
    Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI. Also, brief NOLA preview for HOPA attendees. The Big Easy Debate: sazerac or hurricane? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
    Más Menos
    10 m
  • Tazemetostat Withdrawl and RECITE

    Tazemetostat Withdrawl and RECITE
    Mar 19 2026
    Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
    Más Menos
    15 m
Todas las estrellas
Más relevante
His podcasts are great for pharmacists working in Oncology, especially older guys like me that are fairly new to the world of Onc!

Easy to listen to and great information

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.